These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30398559)

  • 1. Limited Focus in Evaluation of Vaccine Cost-effectiveness-Reply.
    Le P; Rothberg MB
    JAMA Intern Med; 2018 Nov; 178(11):1564. PubMed ID: 30398559
    [No Abstract]   [Full Text] [Related]  

  • 2. Limited Focus in Evaluation of Vaccine Cost-effectiveness.
    Curran D; Van Oorschot D; Buck P
    JAMA Intern Med; 2018 Nov; 178(11):1563-1564. PubMed ID: 30398554
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of the Recommendations of the Advisory Committee on Immunization Practices for the Recombinant Adjuvanted Zoster Subunit Vaccine.
    Le P; Rothberg MB
    JAMA Intern Med; 2018 Sep; 178(9):1277-1278. PubMed ID: 29987323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
    Le P; Rothberg MB
    Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Authors' Reply to Comment on "Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison Between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine".
    Bilcke J; Beutels P
    Pharmacoeconomics; 2022 Oct; 40(10):1013-1014. PubMed ID: 36163539
    [No Abstract]   [Full Text] [Related]  

  • 6. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong.
    You JHS; Ming WK; Lee CF; Tsang OT; Chan PK
    Vaccine; 2018 Jul; 36(31):4610-4620. PubMed ID: 29958739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine.
    Good CB; Hernandez I
    JAMA Intern Med; 2018 Jun; 178(6):873. PubMed ID: 29868745
    [No Abstract]   [Full Text] [Related]  

  • 8. Comment on "Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine".
    Giannelos N; Nishimwe ML; Lecrenier N
    Pharmacoeconomics; 2022 Oct; 40(10):1011-1012. PubMed ID: 36163540
    [No Abstract]   [Full Text] [Related]  

  • 9. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
    Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
    Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines.
    de Boer PT; van Lier A; de Melker H; van Wijck AJM; Wilschut JC; van Hoek AJ; Postma MJ
    BMC Med; 2018 Dec; 16(1):228. PubMed ID: 30518427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of Herpes Zoster Vaccines and Their Economic Value.
    Najafzadeh M
    JAMA Intern Med; 2018 Feb; 178(2):258-259. PubMed ID: 29297047
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of a herpes zoster vaccination program among the French elderly people.
    Belchior E; Lévy-Bruhl D; Le Strat Y; Herida M
    Hum Vaccin Immunother; 2016 Sep; 12(9):2378-82. PubMed ID: 27484158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vaccines against Herpes zoster: Effectiveness, safety, and cost/benefit ratio].
    Ferahta N; Achek I; Dubourg J; Lang PO
    Presse Med; 2016 Feb; 45(2):162-76. PubMed ID: 26724874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the advisory committee on immunization practices' recommendations for use of herpes zoster vaccine.
    Weaver BA;
    J Am Osteopath Assoc; 2011 Oct; 111(10 Suppl 6):S31-3. PubMed ID: 22086893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
    Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
    J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of a Shingles Vaccine Booster for Currently Vaccinated Adults in the U.S.
    Le P; Rothberg MB
    Am J Prev Med; 2017 Dec; 53(6):829-836. PubMed ID: 29153126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
    Le P; Rothberg MB
    JAMA Intern Med; 2018 Feb; 178(2):248-258. PubMed ID: 29297049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing herpes zoster through vaccination.
    Gelb LD
    Ophthalmology; 2008 Feb; 115(2 Suppl):S35-8. PubMed ID: 18243932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
    Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A
    Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.
    Bilcke J; Marais C; Ogunjimi B; Willem L; Hens N; Beutels P
    Vaccine; 2012 Jan; 30(3):675-84. PubMed ID: 22120193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.